aspirin-phosphatidylcholine

attenuates low-dose aspirin-induced ulceration; in randomized clinical trial (11/2010)

Also Known As:

PL2200; aspirin-phosphatidylcholine complex

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        Hydroxybenzoates: 18
        Salicylates: 2339
        Aspirin: 29782
        aspirin-phosphatidylcholine: 2
Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        Glycerophospholipids: 689
        Phosphatidylcholines: 2371
        aspirin-phosphatidylcholine: 2

Experts

1.	Lichtenberger, Lenard M: 2 articles (02/2017 - 02/2011)
2.	Bergeron, Angela L: 1 article (02/2017)
3.	Bick, Roger J: 1 article (02/2017)
4.	Dial, Elizabeth J: 1 article (02/2017)
5.	Fang, Dexing: 1 article (02/2017)
6.	Phan, Tri: 1 article (02/2017)
7.	Poindexter, Brian J: 1 article (02/2017)
8.	Pradhan, Subhashree: 1 article (02/2017)
9.	Vijayan, K Vinod: 1 article (02/2017)
10.	Bhatt, Deepak L: 1 article (02/2011)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 02/01/2017 - "These results suggest that aspirin's chemopreventive effects may be due, in part, to the drug blocking the proneoplastic action of platelets, and the potential use of Aspirin-PC/PL2200 as an effective and safer chemopreventive agent for colorectal cancer and possibly other cancers. "
2.	Ulcer 02/01/2011 - "Overall, 42.2% of aspirin-treated subjects developed multiple erosions and/or ulcers, whereas 22.2% treated with PL2200 developed such damage (P=0.0027). " 02/01/2011 - "We determined acute gastroduodenal erosion and ulceration following low-dose aspirin and aspirin-phosphatidylcholine complex (PL2200) in subjects at risk of aspirin ulcers. "
3.	Peptic Ulcer (Peptic Ulcers) 02/01/2011 - "Gastroduodenal ulcers were observed in 17.6% of aspirin-treated compared with 5.1% of subjects treated with PL2200 (P=0.0069). "
4.	Neoplasms (Cancer) 02/01/2017 - "These results suggest that aspirin's chemopreventive effects may be due, in part, to the drug blocking the proneoplastic action of platelets, and the potential use of Aspirin-PC/PL2200 as an effective and safer chemopreventive agent for colorectal cancer and possibly other cancers. " 02/01/2017 - "We also provide evidence that a novel, gastrointestinal-safe phosphatidylcholine (PC)-associated aspirin, PL2200 Aspirin, possesses the same or more pronounced actions versus unmodified aspirin with regard to antiplatelet effects (in vitro: reducing platelet activation as determined by measuring the release of thromboxane and VEGF in culture medium; in vivo: inhibiting platelet number/activation and extravasation into tumor tissue) and chemoprevention (in vitro: inhibiting colonic cell growth and invasive activity; in vivo: inhibiting colonic dysplasia, inflammation, and tumor mass). "
5.	Inflammation (Inflammations) 02/01/2017 - "We also provide evidence that a novel, gastrointestinal-safe phosphatidylcholine (PC)-associated aspirin, PL2200 Aspirin, possesses the same or more pronounced actions versus unmodified aspirin with regard to antiplatelet effects (in vitro: reducing platelet activation as determined by measuring the release of thromboxane and VEGF in culture medium; in vivo: inhibiting platelet number/activation and extravasation into tumor tissue) and chemoprevention (in vitro: inhibiting colonic cell growth and invasive activity; in vivo: inhibiting colonic dysplasia, inflammation, and tumor mass). "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	aspirin-phosphatidylcholine
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Thromboxanes
5.	Phosphatidylcholines (Phosphatidylcholine)

Related Therapies and Procedures

1.	Chemoprevention